Last reviewed · How we verify

NCT03884504: MDT-1118 Japan

MDT-1118 Japan DT Study

Completed Phase 3 Last updated 21 October 2022
What this trial tests

Phase 3 trial testing Ventricular Assist Device System in Heart Failure in 10 participants. Completed in 19 October 2022.

Timeline
1 May 2019
Primary endpoint
30 December 2020
19 October 2022

Quick facts

Lead sponsorMedtronic Cardiac Rhythm and Heart Failure
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment10
Start date1 May 2019
Primary completion30 December 2020
Estimated completion19 October 2022
Sites1 location across Japan

Drugs / interventions tested

Conditions studied

Sponsor

Medtronic Cardiac Rhythm and Heart Failure — full company profile →

Who can join

20 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety and effectiveness of the MDT-1118 VAD in a patient population for destination therapy (long term support) of advanced heart failure. The collected data will be used to support Japan regulatory application in expanding market approval for destination therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

Other Medtronic Cardiac Rhythm and Heart Failure trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03884504.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing